Conference Coverage

Bariatric surgery tied to 22% lower 5-year stroke risk


 

FROM ASMBS 2021

‘Important,’ ‘good news’ for stroke risk after bariatric surgery

The impact of bariatric surgery on remission of type 2 diabetes is well known, Dr. Williams noted, and other studies have reported how bariatric surgery affects the risk of major adverse cardiovascular events – a composite of stroke, myocardial infarction, coronary artery disease, and all-cause death – including a study presented in the same meeting session.

However, a very large sample size is needed to be able to demonstrate the effect of bariatric surgery on stroke, since stroke is a rare event.

The researchers analyzed data from the Mariner (PearlDiver.) all-payer insurance national claims database of patients in the United States.

They matched 56,514 patients with a body mass index over 35 kg/m2 and comorbidities or a BMI of more than 40 who underwent sleeve gastrectomy or Roux-en-Y gastric bypass during 2010-2019 with 56,514 control patients who did not undergo bariatric surgery.

A year after bariatric surgery, patients in that group had a lower stroke rate than patients in the control group (0.6% vs. 1.2%), and they had close to 50% lower odds of having a stroke (odds ratio, 0.54; 95% CI, 0.47-0.61).

Three years after bariatric surgery, there were 44,948 patients in each group; the rate of stroke was 2.1% in the surgery group and 2.2% in the control group, and there was no significant difference in the odds of having a stroke (OR, 0.96; 95% CI, 0.91-1.00).

Five years after bariatric surgery, there were 27,619 patients in each group; the stroke rate was lower in the bariatric surgery group than in the control group (2.8% vs 3.6%), but reduced odds of stroke was not as great as after 1 year (OR, 0.78; 95% CI, 0.65-0.90).

Dr. Williams has no relevant financial disclosures. Dr. McBride and Dr. Scott disclosed that they are speakers/trainers/faculty advisers for Gore. Dr. Scott is also a consultant for C-SATS (part of Johnson & Johnson).

Pages

Recommended Reading

FDA approves ‘game changer’ semaglutide for weight loss
MDedge Cardiology
New obesity target? Dopamine circuit in brainstem affects satiety
MDedge Cardiology
Waist circumference a marker for NAFL in type 1 diabetes
MDedge Cardiology
‘Twincretin’ meets primary endpoints in five pivotal diabetes trials
MDedge Cardiology
FDA: More metformin extended-release tablets recalled
MDedge Cardiology
Bariatric surgery tied to fewer HFpEF hospitalizations
MDedge Cardiology
Healthy with obesity? The latest study casts doubt
MDedge Cardiology
Bariatric surgery’s cardiovascular benefit extends to 7 years
MDedge Cardiology
Bariatric surgery cuts insulin needs in type 1 diabetes with severe obesity
MDedge Cardiology
Medically suspect criterion can determine bariatric surgery coverage
MDedge Cardiology